Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20027616 | 0.90 | MAPT (0.56) | MAPTALDH1A1TP53HPGDL3MBTL1 | |
| SCHEMBL20028525 | 0.90 | MAPT (0.55) | MAPTALDH1A1TP53HPGDL3MBTL1 | |
| SCHEMBL20027810 | 0.88 | MAPT (0.54) | MAPTALDH1A1TP53HPGDL3MBTL1 | |
| SCHEMBL20028203 | 0.87 | MAPT (0.60) | MAPTALDH1A1TP53HPGDL3MBTL1 | |
| SCHEMBL20027768 | 0.87 | MAPT (0.52) | MAPTALDH1A1TP53L3MBTL1MDM2 | |
| SCHEMBL22896513 | 0.86 | MAPT (0.57) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL22897209 | 0.83 | MAPT (0.68) | MAPTALDH1A1HPGDDHODH | |
| SCHEMBL20027618 | 0.82 | MAPT (0.52) | MAPTALDH1A1TP53HPGDL3MBTL1 | |
| SCHEMBL20028060 | 0.82 | MAPT (0.60) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL22896858 | 0.80 | MAPT (0.50) | MAPTALDH1A1TP53HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885ALDH1A1 4193/4885TP53 1804/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | MAPT 330/4885ALDH1A1 4421/4885TP53 1368/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885ALDH1A1 4193/4885TP53 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.